Radiopharmaceutical Treatment of Malignant Pheochromocytoma
Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent cou...
Gespeichert in:
Veröffentlicht in: | The Journal of nuclear medicine (1978) 1984-02, Vol.25 (2), p.197 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 2 |
container_start_page | 197 |
container_title | The Journal of nuclear medicine (1978) |
container_volume | 25 |
creator | Sisson, James C Shapiro, Brahm Beierwaltes, William H Glowniak, Jerry V Nakajo, Masayuki Mangner, Thomas J Carey, James E Swanson, Dennis P Copp, Jean E Satterlee, Winston G Wieland, Donald M |
description | Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later. |
format | Article |
fullrecord | <record><control><sourceid>pubmed_highw</sourceid><recordid>TN_cdi_pubmed_primary_6726430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6726430</sourcerecordid><originalsourceid>FETCH-LOGICAL-h237t-75165c4c39077fad569c8daa037232e0d0539821ae7bb7d521e6d7b4a9b225b73</originalsourceid><addsrcrecordid>eNotj11LwzAYhYMos05_gtAr7wr56Ju0eCVDnTBRZF6Xt0m6ZjRNSVtk_97CdnU4PIcDzxVJGAjIQEp1TRLKJMsAKNySu3E8UkplURQrspKKy1zQhDz_oHFhaDF61HaenMYu3UeLk7f9lIYm_cTOHXpcyndrg25j8EGfpuDxntw02I324ZJr8vv2ut9ss93X-8fmZZe1XKgpU8Ak6FyLkirVoAFZ6sIgUqG44JYaCqIsOEOr6loZ4MxKo-ocy5pzqJVYk8fz7zDX3ppqiM5jPFUXiYU_nXnrDu2fi7bqZ93ZRWkZH3vPoeIVK5X4B3OSUY8</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</creator><creatorcontrib>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</creatorcontrib><description>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 6726430</identifier><language>eng</language><publisher>United States: Soc Nuclear Med</publisher><subject>3-Iodobenzylguanidine ; Adolescent ; Adrenal Gland Neoplasms - diagnostic imaging ; Adrenal Gland Neoplasms - radiotherapy ; Adult ; Aged ; Drug Evaluation ; Female ; Humans ; Iodine Radioisotopes - administration & dosage ; Iodine Radioisotopes - adverse effects ; Iodobenzenes - administration & dosage ; Iodobenzenes - adverse effects ; Male ; Middle Aged ; Neoplasm Metastasis ; Pheochromocytoma - diagnostic imaging ; Pheochromocytoma - radiotherapy ; Radionuclide Imaging ; Radiotherapy Dosage ; Time Factors</subject><ispartof>The Journal of nuclear medicine (1978), 1984-02, Vol.25 (2), p.197</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6726430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sisson, James C</creatorcontrib><creatorcontrib>Shapiro, Brahm</creatorcontrib><creatorcontrib>Beierwaltes, William H</creatorcontrib><creatorcontrib>Glowniak, Jerry V</creatorcontrib><creatorcontrib>Nakajo, Masayuki</creatorcontrib><creatorcontrib>Mangner, Thomas J</creatorcontrib><creatorcontrib>Carey, James E</creatorcontrib><creatorcontrib>Swanson, Dennis P</creatorcontrib><creatorcontrib>Copp, Jean E</creatorcontrib><creatorcontrib>Satterlee, Winston G</creatorcontrib><creatorcontrib>Wieland, Donald M</creatorcontrib><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</description><subject>3-Iodobenzylguanidine</subject><subject>Adolescent</subject><subject>Adrenal Gland Neoplasms - diagnostic imaging</subject><subject>Adrenal Gland Neoplasms - radiotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - administration & dosage</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Iodobenzenes - administration & dosage</subject><subject>Iodobenzenes - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Pheochromocytoma - diagnostic imaging</subject><subject>Pheochromocytoma - radiotherapy</subject><subject>Radionuclide Imaging</subject><subject>Radiotherapy Dosage</subject><subject>Time Factors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj11LwzAYhYMos05_gtAr7wr56Ju0eCVDnTBRZF6Xt0m6ZjRNSVtk_97CdnU4PIcDzxVJGAjIQEp1TRLKJMsAKNySu3E8UkplURQrspKKy1zQhDz_oHFhaDF61HaenMYu3UeLk7f9lIYm_cTOHXpcyndrg25j8EGfpuDxntw02I324ZJr8vv2ut9ss93X-8fmZZe1XKgpU8Ak6FyLkirVoAFZ6sIgUqG44JYaCqIsOEOr6loZ4MxKo-ocy5pzqJVYk8fz7zDX3ppqiM5jPFUXiYU_nXnrDu2fi7bqZ93ZRWkZH3vPoeIVK5X4B3OSUY8</recordid><startdate>198402</startdate><enddate>198402</enddate><creator>Sisson, James C</creator><creator>Shapiro, Brahm</creator><creator>Beierwaltes, William H</creator><creator>Glowniak, Jerry V</creator><creator>Nakajo, Masayuki</creator><creator>Mangner, Thomas J</creator><creator>Carey, James E</creator><creator>Swanson, Dennis P</creator><creator>Copp, Jean E</creator><creator>Satterlee, Winston G</creator><creator>Wieland, Donald M</creator><general>Soc Nuclear Med</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198402</creationdate><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><author>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h237t-75165c4c39077fad569c8daa037232e0d0539821ae7bb7d521e6d7b4a9b225b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>3-Iodobenzylguanidine</topic><topic>Adolescent</topic><topic>Adrenal Gland Neoplasms - diagnostic imaging</topic><topic>Adrenal Gland Neoplasms - radiotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - administration & dosage</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Iodobenzenes - administration & dosage</topic><topic>Iodobenzenes - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Pheochromocytoma - diagnostic imaging</topic><topic>Pheochromocytoma - radiotherapy</topic><topic>Radionuclide Imaging</topic><topic>Radiotherapy Dosage</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sisson, James C</creatorcontrib><creatorcontrib>Shapiro, Brahm</creatorcontrib><creatorcontrib>Beierwaltes, William H</creatorcontrib><creatorcontrib>Glowniak, Jerry V</creatorcontrib><creatorcontrib>Nakajo, Masayuki</creatorcontrib><creatorcontrib>Mangner, Thomas J</creatorcontrib><creatorcontrib>Carey, James E</creatorcontrib><creatorcontrib>Swanson, Dennis P</creatorcontrib><creatorcontrib>Copp, Jean E</creatorcontrib><creatorcontrib>Satterlee, Winston G</creatorcontrib><creatorcontrib>Wieland, Donald M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sisson, James C</au><au>Shapiro, Brahm</au><au>Beierwaltes, William H</au><au>Glowniak, Jerry V</au><au>Nakajo, Masayuki</au><au>Mangner, Thomas J</au><au>Carey, James E</au><au>Swanson, Dennis P</au><au>Copp, Jean E</au><au>Satterlee, Winston G</au><au>Wieland, Donald M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>1984-02</date><risdate>1984</risdate><volume>25</volume><issue>2</issue><spage>197</spage><pages>197-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</abstract><cop>United States</cop><pub>Soc Nuclear Med</pub><pmid>6726430</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | The Journal of nuclear medicine (1978), 1984-02, Vol.25 (2), p.197 |
issn | 0161-5505 1535-5667 |
language | eng |
recordid | cdi_pubmed_primary_6726430 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | 3-Iodobenzylguanidine Adolescent Adrenal Gland Neoplasms - diagnostic imaging Adrenal Gland Neoplasms - radiotherapy Adult Aged Drug Evaluation Female Humans Iodine Radioisotopes - administration & dosage Iodine Radioisotopes - adverse effects Iodobenzenes - administration & dosage Iodobenzenes - adverse effects Male Middle Aged Neoplasm Metastasis Pheochromocytoma - diagnostic imaging Pheochromocytoma - radiotherapy Radionuclide Imaging Radiotherapy Dosage Time Factors |
title | Radiopharmaceutical Treatment of Malignant Pheochromocytoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T23%3A59%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiopharmaceutical%20Treatment%20of%20Malignant%20Pheochromocytoma&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Sisson,%20James%20C&rft.date=1984-02&rft.volume=25&rft.issue=2&rft.spage=197&rft.pages=197-&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/&rft_dat=%3Cpubmed_highw%3E6726430%3C/pubmed_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6726430&rfr_iscdi=true |